Want to see CH:YPSN full AI Analyst Report?
YPSN Stock Chart & Stats
CHF382.40
CHF9.40(2.46%)
At close: 4:00 PM EDT
CHF382.40
CHF9.40(2.46%)
Day’s Range― - ―
52-Week RangeCHF260.50 - CHF419.50
Previous CloseN/A
Volume9.81K
Average Volume (3M)17.31K
Market Cap
CHF5.06B
Enterprise ValueCHF4.81B
Total Cash (Recent Filing)CHF28.56M
Total Debt (Recent Filing)CHF260.77M
Price to Earnings (P/E)23.6
Beta0.65
Next Earnings
Nov 11, 2026EPS Estimate
5.25Next Dividend Ex-DateN/A
Dividend Yield1.14%
Share Statistics
EPS (TTM)16.31
Shares Outstanding13,149,739
10 Day Avg. Volume12,508
30 Day Avg. Volume17,306
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.02
Price to Sales (P/S)5.14
P/FCF Ratio-229.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF373.67Price Target Upside-2.28% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)13.21
Revenue Forecast (FY)CHF710.95M
Bulls Say, Bears Say
Bulls Say
High And Improving ProfitabilityYpsomed delivered materially higher profitability and operating cash flow, with EBIT margins near 33% and net income jumping to CHF 221.9m. Strong margin structure and elevated operating cash flow underpin durable earnings power, funding reinvestment and supporting mid‑term ROCE targets.
Robust Project Pipeline And Deal FlowA deep, diversified pipeline (≈260 products, 80 launched, 180 in development) and record deal wins provide multi‑year revenue visibility. A ~70% hit rate and >130 clients with low customer concentration support durable commercial momentum and lower project execution risk over 2–5 years.
Capacity Expansion And Faster CommercializationSignificant factory expansions (China, Schwerin, US) plus service improvements (Clear‑to‑Clinic reduced to ~6 months) increase scalable production and speed to market. Customer co‑financing and tool shop capacity enhance unit economics and competitive positioning long term.
Bears Say
Persistent Negative Free Cash FlowDespite strong operating cash flow, persistent negative free cash flow reflects heavy capex and working‑capital use. Continued FCF deficits constrain financial flexibility, increase reliance on financing or asset sales, and could limit buybacks/dividends until investment cycles normalize.
Recent Revenue Decline And Reduced Contract ManufacturingA reported group revenue decline and the deliberate phase‑out of contract manufacturing reduce near‑term reported sales by material single‑digit millions. This lowers short‑term revenue floor and adds execution pressure to convert pipeline projects into replacement commercial volumes.
Ramp‑up, Stranded Costs And One‑offs From TransformationLarge footprint and capacity projects create temporary empty capacity, ramp‑up inefficiencies and occasional impairments. These execution risks can compress margins and cash flow during multi‑year scaling, making delivery of mid‑term ROCE and margin targets dependent on smooth operational rollouts.
YPSN FAQ
What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest stock price was CHF260.50 and its highest was CHF419.50 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.06B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s upcoming earnings report date is Nov 11, 2026 which is in 99 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on May 20, 2026. The company reported CHF6.11 earnings per share for the quarter, beating the consensus estimate of CHF6 by CHF0.11.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Overvalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays a Annually dividend of CHF4.4 which represents an annual dividend yield of 1.14%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 5.25.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,149,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.11 in its last earnings report, beating expectations of CHF6. Following the earnings report the stock price went up 9.33%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in CH:YPSN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
YPSN Stock 12 Month Forecast
Average Price Target
CHF373.67
▼(-2.28% Downside)